Silence Therapeutics PLC (SLN) — Capital Reinvestment Ratio
Silence Therapeutics PLC (SLN) has a Capital Reinvestment Ratio of 0.00x as of June 2026, meaning it reinvests 0% of its operating cash flow ($1.49 Million) in capital expenditures ($3.00). Check Silence Therapeutics PLC (SLN) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Silence Therapeutics PLC Capital Reinvestment Ratio (2019–2021)
This chart tracks Silence Therapeutics PLC's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see SLN operating cash flow.
Annual Capital Reinvestment Ratio for Silence Therapeutics PLC (2019–2021)
Year-by-year Capital Reinvestment Ratio for Silence Therapeutics PLC from 2019 to 2021. See Silence Therapeutics PLC free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.20x | $9.19 Million | $1.80 Million | ▲ +3661.1% |
| 2019 | 0.01x | $1.73 Million | $9.00K | — |